Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAT study of OCUL101 versus aflibercept in neovascular age-related macular degeneration
2026-526648-11-00Phase 3Authorised
- Sponsor
- Oculgen Biomedical
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of OCUL101 in exudative macular degeneration (3 arms), sponsored by Oculgen Biomedical. Primary endpoints: Incidence and rate of adverse events and Change in best-corrected visual acuity at Week 36. Planned start Sep 2026; status: authorised.
02
Drugs
OCUL101
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2026-526648-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526648-11-00.